Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin-alpha 1 for Adjuvant Treatment in High-risk Stage II/III Colorectal Cancer
NCT05086614Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of thymosin alpha 1 in colorectal cancer (CRC), sponsored by Fudan University. Started Apr 2021; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05086614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086614.